Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Role of myeloid-derived suppressor cells in autoimmune disease
Kristen R Crook, Peng Liu, Department of Medicine, Thurston Arthritis Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
Author contributions: Crook KR and Liu P designed the review, wrote the paper, and approved for publication.
Correspondence to: Peng Liu, MD, PhD, Associate Professor, Department of Medicine, Thurston Arthritis Research Center, School of Medicine, University of North Carolina at Chapel Hill, 3300 Thurston Building, CB# 7280, 104 Manning Drive, Chapel Hill, NC 27599, United States. liupz@med.unc.edu
Telephone: +1-919-9660570 Fax: +1-919-9669269
Received: October 25, 2013
Revised: December 12, 2013
Accepted: January 17, 2014
Published online: March 27, 2014
Processing time: 152 Days and 7.6 Hours
Revised: December 12, 2013
Accepted: January 17, 2014
Published online: March 27, 2014
Processing time: 152 Days and 7.6 Hours
Core Tip
Core tip: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of cells with immunosuppressive abilities. MDSCs inhibit T cell function and regulate immune responses in cancer and autoimmune diseases. Therapeutic administration of MDSCs in the mouse models of multiple sclerosis, rheumatoid arthritis, and diabetes has shown promising results. Thus, MDSCs have potential in cell-based treatments of autoimmune disorders. However, the role of MDSCs in autoimmunity is complex and not fully understood. Further studies are needed before new therapies can be implemented.